{"id":21897,"date":"2025-07-16T08:30:00","date_gmt":"2025-07-16T06:30:00","guid":{"rendered":"https:\/\/vasro.de\/?p=21897"},"modified":"2025-07-10T19:19:11","modified_gmt":"2025-07-10T17:19:11","slug":"biotech-aktienbewertungsmodelle-fortgeschrittene-prognosetechniken","status":"publish","type":"post","link":"https:\/\/vasro.de\/en\/biotech-aktienbewertungsmodelle-fortgeschrittene-prognosetechniken\/","title":{"rendered":"Biotech Stock Valuation Models: Advanced Forecasting Techniques Explained"},"content":{"rendered":"\n
\n

Advanced forecasting techniques such as the Discounted Cash Flow model and real options valuation<\/a> shape the valuation of biotech companies because they incorporate long-term development and the unique uncertainties of the sector. Biotech stock valuation models, in particular, account for the complex risks and high volatility that classic methods like the price-earnings ratio often fail to adequately capture.<\/p>\n

The following table shows how biotech differs from other industries in terms of research spending, earnings volatility, and market risk:<\/p><\/blockquote>\n

\n \n \n \n \n \n \n <\/colgroup>\n \n \n \n \n \n \n \n

Metric<\/p><\/th>\n

Biotech Sector<\/p><\/th>\n

Pharma Industry<\/p><\/th>\n

Other Industries<\/p><\/th>\n <\/tr>\n

R&D Intensity (R&D to Assets)<\/p><\/td>\n

38%<\/p><\/td>\n

25%<\/p><\/td>\n

3%<\/p><\/td>\n <\/tr>\n

Earnings Volatility<\/p><\/td>\n

High<\/p><\/td>\n

Lower<\/p><\/td>\n

N\/A<\/p><\/td>\n <\/tr>\n

Market Risk<\/p><\/td>\n

High<\/p><\/td>\n

Lower<\/p><\/td>\n

N\/A<\/p><\/td>\n <\/tr>\n

Size Risk<\/p><\/td>\n

High<\/p><\/td>\n

Lower<\/p><\/td>\n

N\/A<\/p><\/td>\n <\/tr>\n

Regulatory Response<\/p><\/td>\n

More negative<\/p><\/td>\n

Less negative<\/p><\/td>\n

N\/A<\/p><\/td>\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n

\n
\n \"Bar\n <\/div>\n <\/figure>\n

This data<\/a> highlights why innovative biotech stock valuation models are becoming increasingly important for analyzing biotech companies.<\/p>\n